Anifrolumab Malignancy and Serious Infections Study

Trial Identifier: D3461R00046
Sponsor: AstraZeneca
Collaborator:
IQVIA
Start Date: January 2026
Primary Completion Date: November 2031
Study Completion Date: November 2031
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Denmark, Denmark Copenhagen, Denmark, Denmark, 23000
France, France Charenton-le-Pont, France, France, 94220
Germany, Germany Essen, Germany, Germany, 45128
Spain, Spain Barcelona, Spain, Spain, 08007